What 2026 funding is rewarding now

The industry has been measuring the wrong thing with the wrong dataset

Somewhere in North America, a consumer is sitting in a NECTAR booth tasting her seventh coded sample of the afternoon. She scores it zero to nine for acceptability and writes one sentence about texture. What she is doing is the most serious consumer sensory work in alt-protein. What the booth does not see is whether she ever buys the product again. This episode argues that the industry has been reading the wrong half of the sensory data. The NECTAR 2025 panel shows taste parity is closing across plant-based categories. Texture parity is not. And even where texture is approaching parity, the measurement that actually predicts commercial outcome is not the blind panel score. It is the repeat-purchase rate sitting in scan panels that most brand teams do not track with the same discipline they apply to taste tests. Twelve minutes. Two reversals. One counterintuitive call on the category type investors keep mispricing. Press play. The diagnostic question from this episode:"If the only thing you could measure about your product was repeat purchase, would you still be making the same formulation decisions?" This episode continues a four-piece FoodEdge arc. Issue 20 (rent before build), Issue 21 (downstream processing moat), Issue 23 (platforms should start as ingredient companies), and now S02E06 (taste, texture, repeat purchase). Each one is about commercial discipline coming before optionality. Read the prior posts on FoodEdge before or after listening. Get full access to Food Edge at amadamek.substack.com/subscribe [https://amadamek.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4]

What 2026 funding is rewarding now

In 2021, two precision fermentation companies raised on similar promises. Vivici closed a thirty-two point five million euro Series A, backed by dsm-firmenich and Fonterra. Believer Meats raised over three hundred and forty million dollars and achieved regulatory clearance in the United States. Four years later, only one of them can still point to a document that would survive an outside audit. This episode argues that the real question about the twenty twenty-six funding market is not whether investors have learned discipline. It is whether they have noticed that the filter has moved outside the room entirely. Evidence portability, not conviction, is what is getting capital deployed now. The parties that can witness a moat from the inside are the ones writing the documents that determine which Food Biotech startups raise their next round. And the sector is still pitching the wrong companies. Twelve minutes. One reversal. One counterintuitive call on the company type everyone is mispricing. Press play. The diagnostic question from this episode: ”If an investor called you tomorrow, not next week, tomorrow, and asked to see one document from your company. Not a deck. Not a data room index. Not a LinkedIn post. One document, signed by somebody outside your building, that proved your moat was real. Could you produce it?” This episode closes a three-piece arc with Issue 20 (rent before build) and Issue 21 (the downstream processing moat). Read both on FoodEdge before or after listening. Get full access to Food Edge at amadamek.substack.com/subscribe [https://amadamek.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4]

The anti-UPF era will split FoodTech in two

The ultra-processed foods debate is no longer only a nutrition argument. It is infrastructure. WHO formally initiated guideline work on UPF consumption in 2025. FDA and USDA launched a joint process to build a uniform federal definition. The moment institutions create language, markets start using it as a shortcut. And shortcuts reprice categories before science fully settles them. This episode breaks down what that sequencing means for founders and investors. I am not arguing that every processed product is harmful, or that FoodTech is about to collapse under a wave of public health sentiment. I am arguing something more specific: in the next capital cycle, ultra-processed risk will become a standard screen in FoodTech diligence, alongside regulatory, margin, and formulation risk. The founders and investors who understand that now will be positioned differently from those who discover it when the term sheet changes. Thanks for reading Food Edge! This post is public so feel free to share it. We examine the evidence without pretending it is cleaner than it is. The 2024 BMJ umbrella review across forty-five meta-analyses. The 2025 Nature Medicine randomised crossover trial that matched both diets on nutritional guidelines and still found a processing signal. What the data actually proves, what it does not prove, and why the burden of explanation has shifted from regulators to founders. From there, I introduce a three-bucket framework: processing-defensible, processing-tolerable, and processing-fragile. The third bucket gets hit first. The uncomfortable part is that a significant share of the market currently believes it sits in bucket one. The broader message is structural. A 2026 Deloitte survey found that sixty-eight percent of Americans viewed ultra-processed foods as worse for health, whilst sixty-nine percent could not explain what ultra-processed foods actually are. High suspicion, low understanding, fast judgment. That is not a communications problem. That is a valuation problem in slow motion. If you are four to twelve weeks from investor conversations, this episode is a stress test of your processing narrative. Can you explain in one sentence why your product is made the way it is? If definitions tighten, does your story get stronger or weaker? And which processing steps are genuinely necessary, versus inherited from a decade of convenience logic nobody ever questioned? What looks like nutrition debate today becomes valuation logic tomorrow. Listen to the episode. And audit your processing architecture before investors do. - Adam Get full access to Food Edge at amadamek.substack.com/subscribe [https://amadamek.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4]

Geography is no longer a go-to-market slide.

Japan’s recent FoodTech upgrade is not a public relations moment. It is a structural signal. By naming FoodTech a national strategic sector alongside artificial intelligence and semiconductors, Japan has flipped the order of innovation: policy first, infrastructure second, evidence third, narrative last. This episode breaks down what that sequencing means for founders and investors. We analyse Japan not as a hype cycle, but as an evidence engine, from cellular agriculture infrastructure to population-scale microbiome datasets. The key insight is simple: when governments fund infrastructure that generates longitudinal data, founders inherit credibility before they even pitch. We then examine the genome-edited high GABA tomato as a case study in the Narrative-Evidence Gap. Mechanism and regulatory clearance were not enough. Trust-layer evidence lagged. Distribution hesitated. The lesson is clear: regulatory approval does not automatically convert into consumer legitimacy. From there, we build an evidence credibility ladder using recent FoodBioTech moves. Regulatory status as a distribution ticket. Steel and concrete as proof of scalability. Infrastructure monetisation as strategic defensibility. Supply-chain piggybacking as accelerated validation. The common thread is that serious players are presenting regulators, factories, tools, and data assets as proof, not adjectives. The broader message is structural. In two thousand twenty six, geography determines where lab data, plant economics, regulatory dossiers, and trust signals can actually be built. Fundraising narratives that ignore this layer risk becoming innovation theatre at the national scale. If you are raising capital within the next twelve to eighteen months, this episode is a stress test of your geography story. Can your chosen country generate decision-grade evidence fast enough to support your claims, or are you relying on slides and assumptions? I recommend following Jasper Sturtewagen [https://substack.com/profile/12356440-jasper-sturtewagen], whose writing dissects European innovation, policy architecture, and capital allocation with unusual clarity and structural depth. You can subscribe to his Substack here: Listen to the episode. And audit your geography before investors do. - Adam Get full access to Food Edge at amadamek.substack.com/subscribe [https://amadamek.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4]

Food as Medicine 3.0

Food as Medicine 3.0 marks a structural shift, not a trend. Appetite-suppressing GLP-1 drugs, AI-driven multi-omics, and tightening regulation are forcing food to behave less like lifestyle branding and more like pharmaceutical infrastructure. This episode breaks down how drug-led appetite control is already reshaping food demand, shrinking calorie intake, and pushing brands toward nutrient density, digestive tolerance, and dosing-aware design rather than volume and indulgence. We explore how food is moving from macronutrients to molecules, targeting inflammation, metabolic markers, microbiome modulation, and aging pathways with measurable outcomes. What once lived in academic journals is now entering commercial pipelines, backed by biomarker data, clinical-style validation, and regulatory dossiers. The real bottleneck is no longer technology, but alignment between evidence, claims, and governance across regions. The episode also maps the regulatory divergence shaping winners and losers. The EU advances through evidence-led claims and public-private partnerships, the US navigates gray zones under FDA oversight and payer pressure, and Asia experiments with rapid pilots and digital health integration. On the investment side, capital is concentrating around platforms that prove impact, integrate diagnostics, and speak the language of regulators and insurers, not just consumers. The core message is simple: food that cannot demonstrate measurable therapeutic value will struggle to survive in a drug-shaped nutrition economy. I recommend following Valentina Chiran-Buda, whose work treats quality, food safety, sustainability, and health as one coherent system rather than disconnected disciplines. You can subscribe to her Substack here: where she publishes her notes on how science, regulation, culture, and trust intersect in real-world food systems. Listen to the podcast episode! And enjoy. - Adam Get full access to Food Edge at amadamek.substack.com/subscribe [https://amadamek.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4]